Ascelia Pharma AB

Stocks

Real-time Estimate Cboe Europe 05:11:42 27/10/2026 pm IST			5-day change	1st Jan Change
0.5220 ^SEK	-1.14%		+0.39%	-83.83%

12/10	Redeye sees potential path forward for Ascelia after FDA update	FW
12/10	Ascelia Pharma AB - Special Call

Published on 10/12/2026 at 01:06 pm IST - Modified on 10/12/2026 at 02:05 pm IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to Ascelia Pharma Investor Update October 2026. [Operator Instructions]

Now I will hand the conference over to the

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

12/10	Redeye sees potential path forward for Ascelia after FDA update	FW
12/10	Ascelia Pharma AB - Special Call
12/10	DNB Carnegie maintains 50 percent probability of approval for Ascelia Pharma's Orviglance	FW
12/10	US FDA Requests Additional Clinical Evidence for Ascelia Pharma's Orviglance Application	MT
12/10	Ascelia Pharma: FDA requires additional clinical evidence for Orviglance	FW
11/10	Ascelia Pharma AB Provides Orviglance Update Following Fda Type A Meeting	CI
24/09	Ascelia study on Orviglance published in scientific journal	FW
10/09	Ascelia Pharma has held FDA meeting on Orviglance	FW
24/08	DNB Carnegie lowers bottom end of valuation range for Ascelia Pharma	FW
20/08	Ascelia Pharma AB, H1 2026 Earnings Call, Aug 20, 2026
20/08	Ascelia Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	Ascelia Pharma narrowed its loss in the second quarter	FW
20/08	Calendar Thursday, August 20	FW
17/08	Ascelia Pharma to Meet With US FDA on Orviglance Drug Application	MT
17/08	Ascelia Pharma to hold FDA meeting on Orviglance on September 9	FW